Bionano Genomics announced its participation in the Association for Molecular Pathology, AMP, 2023 Annual Meeting and Expo with a broad range of content covering the utility of optical genome mapping, OGM. for cell and gene therapy and cancer research, including scientific workshops and poster presentations from Bionano and researchers from across the genomics landscape. A corporate workshop session titled “Structural Variant Insights from Adult and Pediatric CNS Tumors: Powered by OpticalGenome Mapping,” will be hosted by Dr. Chaubey, and will include a presentation from Drs. Terraf, Kolhe, and Bornhorst on their research regarding the role of SVs in CNS tumors. A second corporate workshop session, titled “Revolutionizing Cytogenomics with Optical Genome Mapping in Hematological Malignancies,” will begin with a brief overview of the OGM workflow by Dr. Hastie, followed by Drs. Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Genomics downgraded to Hold from Buy at Maxim
- Bionano Genomics reports Q3 revenue $9.32M, consensus $9.08M
- Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Genomics announces OGM was included in a medical school textbook
- Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023